Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.53 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 2/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.41 |
| ▸ | GCGR | P47871 | 2/20 | 0.41 |
| ▸ | GIPR | P48546 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171648 | 0.89 | TRPV1 (0.56) | TRPV1HTRA1HIF1ANPC1HTT | |
| SCHEMBL2172774 | 0.83 | PTPN1 (0.46) | PTPN1PTPRBGPR34 | |
| SCHEMBL283213 | 0.82 | TRPV1 (0.58) | TRPV1HIF1AMAPTNPC1HTT | |
| SCHEMBL2174194 | 0.80 | PTPRB (0.51) | PTPN1PTPRBMAPTNPC1RAB9A | |
| SCHEMBL2185969 | 0.75 | TRPV1 (0.59) | TRPV1HIF1AGCGRGIPRMAPT | |
| SCHEMBL12407047 | 0.75 | TRPV1 (0.61) | TRPV1HIF1AMAPTNPC1HTT | |
| SCHEMBL2171605 | 0.74 | TRPV1 (0.58) | TRPV1HIF1AMAPTNPC1HTT | |
| SCHEMBL4383737 | 0.74 | TRPV1 (0.58) | TRPV1HIF1ANPC1HTTRAB9A | |
| SCHEMBL2173420 | 0.74 | TRPV1 (0.60) | TRPV1HIF1AMAPTNPC1HTT | |
| SCHEMBL5668546 | 0.74 | IGF1R (0.49) | TRPV1HIF1AMAPTNPC1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | TRPV1 3477/4885HTRA1 3978/4885PTPN1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.